NZ560327A - Compositions and methods for less immunogenic protein formulations - Google Patents

Compositions and methods for less immunogenic protein formulations

Info

Publication number
NZ560327A
NZ560327A NZ560327A NZ56032706A NZ560327A NZ 560327 A NZ560327 A NZ 560327A NZ 560327 A NZ560327 A NZ 560327A NZ 56032706 A NZ56032706 A NZ 56032706A NZ 560327 A NZ560327 A NZ 560327A
Authority
NZ
New Zealand
Prior art keywords
protein
fviii
lipid
liposomes
complex
Prior art date
Application number
NZ560327A
Other languages
English (en)
Inventor
Vivek S Purohit
Sathyamagalam Balasubramanian
Robert M Straubinger
Karthik Ramani
Original Assignee
Univ New York State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York State Res Found filed Critical Univ New York State Res Found
Publication of NZ560327A publication Critical patent/NZ560327A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NZ560327A 2005-02-02 2006-02-02 Compositions and methods for less immunogenic protein formulations NZ560327A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/049,134 US7351688B2 (en) 2003-02-05 2005-02-02 Compositions and methods for less immunogenic protein formulations
PCT/US2006/003779 WO2006084095A1 (en) 2005-02-02 2006-02-02 Compositions and methods for less immunogenic protein formulations

Publications (1)

Publication Number Publication Date
NZ560327A true NZ560327A (en) 2011-03-31

Family

ID=36777576

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ560327A NZ560327A (en) 2005-02-02 2006-02-02 Compositions and methods for less immunogenic protein formulations

Country Status (7)

Country Link
US (1) US7351688B2 (enExample)
EP (1) EP1858532A4 (enExample)
JP (1) JP2008528696A (enExample)
AU (1) AU2006210609A1 (enExample)
CA (1) CA2596280A1 (enExample)
NZ (1) NZ560327A (enExample)
WO (1) WO2006084095A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007117469A2 (en) 2006-03-30 2007-10-18 The Research Foundation Of State University Of New York Compositions of less immunogenic and long-circulating protein-lipid complexes
EP1988101A1 (en) * 2007-05-04 2008-11-05 Novo Nordisk A/S Improvement of factor VIII polypeptide titers in cell cultures
US20120164189A1 (en) * 2009-07-07 2012-06-28 Balu-Iyer Sathy V Lipidic Compositions for Induction of Immune Tolerance
US10617640B2 (en) * 2009-07-07 2020-04-14 The Research Foundation For The State University Of New York Phosphoserine containing compositions for immune tolerance induction
WO2011016043A2 (en) * 2009-08-06 2011-02-10 Technion Research & Development Foundation Ltd. Antibiotic drug delivery and potentiation
US10138290B2 (en) 2010-10-05 2018-11-27 Novo Nordisk Healthcare Ag Process for protein production
JP6347743B2 (ja) * 2011-05-05 2018-06-27 マティナス バイオファーマ ナノテクノロジーズ，インコーポレーテッド コクリエート組成物およびその製造および使用方法
US10064922B2 (en) * 2011-10-06 2018-09-04 The Research Foundation For The State University Of New York Compositions and methods for immune tolerance induction
WO2015048145A1 (en) 2013-09-24 2015-04-02 The Research Foundation For The State University Of New York Compositions and methods for reducing antigen-specific immunogenicity
US11083782B2 (en) * 2016-04-05 2021-08-10 The Research Foundation For The State University Of New York Phosphoserine containing compositions for immune tolerance induction

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4127502A (en) 1977-06-10 1978-11-28 Eastman Kodak Company Stabilizers for reconstituted, lyophilized samples
US4795806A (en) 1987-07-16 1989-01-03 Miles Laboratories, Inc. Phospholipid affinity purification of Factor VIII:C
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
WO1998048837A1 (en) 1997-04-30 1998-11-05 Enzon, Inc. Polyalkylene oxide-modified single chain polypeptides
SE513221C2 (sv) * 1998-04-17 2000-07-31 Net Insight Ab Förfarande och anordning för allokering av tidluckor till en kanal i ett kretskopplat tidsmultiplexerat nät
MXPA00010241A (es) 1998-04-27 2004-09-06 Opperbas Holding Bv Composicion farmaceutica que comprende el factor viii y liposomas neutrales..
US20020132982A1 (en) * 2000-11-30 2002-09-19 Balasubramanian Sathyamangalam V. AHF associated dispersion system and method for preparation
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
WO2003013245A1 (en) 2001-08-07 2003-02-20 Wisconsin Alumni Research Foundation Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy
US20040229793A1 (en) 2003-02-05 2004-11-18 Balasubramanian Sathyamangalam V. Compositions and methods for less immunogenic protein formulations

Also Published As

Publication number Publication date
US20050227913A1 (en) 2005-10-13
US7351688B2 (en) 2008-04-01
AU2006210609A1 (en) 2006-08-10
EP1858532A1 (en) 2007-11-28
CA2596280A1 (en) 2006-08-10
EP1858532A4 (en) 2011-05-11
JP2008528696A (ja) 2008-07-31
WO2006084095A1 (en) 2006-08-10

Similar Documents

Publication Publication Date Title
EP2451485B1 (en) Lipidic compositions for induction of immune tolerance
JP5160534B2 (ja) 低免疫原性および長時間循環性タンパク質−脂質複合体の組成物
Ramani et al. Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A
US7351688B2 (en) Compositions and methods for less immunogenic protein formulations
US20040229793A1 (en) Compositions and methods for less immunogenic protein formulations
Miclea et al. Development and characterization of lipidic cochleate containing recombinant factor VIII
US7875288B2 (en) Method for treating blood coagulation disorders
EP3049103B1 (en) Compositions and methods for reducing antigen-specific immunogenicity
JP2008544990A (ja) 低免疫原性蛋白質−脂質複合体に関する組成物および方法
US10064922B2 (en) Compositions and methods for immune tolerance induction
Peng et al. Phosphatidylinositol containing lipidic particles reduces immunogenicity and catabolism of factor VIII in hemophilia a mice
EP1668358B1 (en) Reconstitution medium for protein and peptide formulations
WO2007123691A2 (en) Method for treating blood coagulation disorders
Ramani et al. Preclinical Evaluation of PEGylated Liposomal-Recombinant Human FVIII in a Murine Model of Hemophilia A
Miclea et al. Effect of phosphatidylethanolamine and polyethylene glycol on the immunogenicity and pharmacokinetic properties of PS containing liposomal B domain deleted rFVIII in a murine model of hemophilia A
Ramani et al. Liposomal Nano-and Micro-Particulates Containing Phosphatidylserine Reduce the Immunogenicity of Recombinant Human Factor VIII (rFVIII) in a Murine Model of Hemophilia A
MX2008000223A (en) Compositions and methods for less immunogenic pr0tein-lip1d complexes

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 02 FEB 2016 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS

Effective date: 20130117

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 FEB 2017 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD

Effective date: 20160203

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 FEB 2018 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD

Effective date: 20161229

LAPS Patent lapsed